» Articles » PMID: 34164546

Intravenous Fluids for Pain Management in Head and Neck Cancer Patients Undergoing Chemoradiation

Overview
Journal Ann Transl Med
Date 2021 Jun 24
PMID 34164546
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pain due to oral mucositis affects the majority of patients receiving chemoradiation (CRT) for head and neck cancer (HNC), and often results in dehydration. Anecdotally, intravenous (IV) fluids administered during treatment for the resultant dehydration was found to alleviate this pain. The purpose of this retrospective study was to evaluate the effectiveness of IV fluids as a method pain management in this patient population.

Methods: Patients with oral mucositis pain, secondary to CRT for HNC, were given IV fluids according to standard clinic protocol. Patients were evaluated using orthostatic vital signs and prospectively surveyed pre- and post-IV fluid administration, which included the Visual Analog Scale (VAS) for pain. Difference in pain pre- and post-IV fluid administration was evaluated using a two-tailed paired Student's -test.

Results: Twenty-four patients with a total of 31 fluid administrations was available for analysis. Twenty-three patients were receiving or had recently completed CRT. One patient was receiving radiation alone. Six instances of fluid administration were excluded due to: refusal to complete the survey, concurrent pulmonary embolism, concurrent pain medication, and drug seeking behavior. Average pain score decreased from 6.5 [standard deviation (SD) 2.1] prior to IV fluids to 4.0 (SD 2.4) following fluid administration (P<0.001).

Conclusions: To our knowledge, this is the first report directly correlating IV fluid administration with pain relief, even in the absence of orthostasis. Our findings indicate that in patients undergoing CRT for HNC, the use of IV fluids alone was effective in acutely and significantly reducing pain secondary to oral mucositis.

Citing Articles

Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital.

Hamzi H, Binhassan A, Najmeldin A, Alhariri E, Elhussein B, Althibani N J Egypt Natl Canc Inst. 2024; 36(1):38.

PMID: 39617846 DOI: 10.1186/s43046-024-00247-x.


Improving Practice in a Head and Neck Oncology Clinic Using the PRO-CTCAE Tool.

Ruddy R, Carter B, Giuliante M, Walton A J Adv Pract Oncol. 2024; 15(5):303-310.

PMID: 39328382 PMC: 11424159. DOI: 10.6004/jadpro.2024.15.5.2.


Severe Oral Mucositis After Intensity-Modulated Radiation Therapy for Head and Neck Cancer.

Iovoli A, Turecki L, Qiu M, Khan M, Smith K, Yu H JAMA Netw Open. 2023; 6(10):e2337265.

PMID: 37819659 PMC: 10568356. DOI: 10.1001/jamanetworkopen.2023.37265.

References
1.
Balbin J, Nerenberg R, Baratloo A, Friedman B . Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am J Emerg Med. 2016; 34(4):713-6. DOI: 10.1016/j.ajem.2015.12.080. View

2.
Han H, Hermann G, Ma S, Iovoli A, Wooten K, Arshad H . Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients. Oral Oncol. 2020; 109:104854. PMC: 7738364. DOI: 10.1016/j.oraloncology.2020.104854. View

3.
Richer L, Craig W, Rowe B . Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache. 2014; 54(9):1496-505. DOI: 10.1111/head.12443. View

4.
McCloskey S, Jaggernauth W, Rigual N, Hicks Jr W, Popat S, Sullivan M . Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of.... Am J Clin Oncol. 2009; 32(6):587-91. DOI: 10.1097/COC.0b013e3181967dd0. View

5.
Bruera E, Hui D, Dalal S, Torres-Vigil I, Trumble J, Roosth J . Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol. 2012; 31(1):111-8. PMC: 3530688. DOI: 10.1200/JCO.2012.44.6518. View